Novartis Q4 Results
Content
Click below to navigate
through the document
. and to deliver >20 key submissions in core therapeutic areas by 2028
INNOVATION
↓
↑
Company overview
Financial review
Conclusions
Appendix
Select key assets submission schedule
Core therapeutic
areas
2024
References
CRM
atrasentan
IgAN1
Immunology
iptacopan
IgAN1
2025
pelacarsen
CVRR-Lp(a)
CosentyxⓇ
Tendinopathy
PluvictoⓇ
MHSPC2
CosentyxⓇ
Polymyalgia rheumatica
ianalumab
2L ITP
2026-2028
ianalumab
Sjögren's syndrome
ianalumab
Lupus Nephritis
ianalumab
SLE
me
PluvictoⓇ
Oligometastatic PC
remibrutinib
CINDU
remibrutinib
Multiple sclerosis
Neuroscience
iptacopan
ZolgensmaⓇ
C3G
SMA IT
Oncology
remibrutinib
CSU
PluvictoⓇ
mCRPC, pre-taxane
ScemblixⓇ
CML 1L
1. US submission for accelerated approval.
2. Event-driven trial endpoint.
CosentyxⓇ
GCA
LeqvioⓇ
Hyperlipidemia ped
□ NOVARTIS | Reimagining Medicine.
را
ianalumab
1L ITP
iptacopan
IC-MPGN
ianalumab
LeqvioⓇ
WAIHA
CVRR-LDLC
zigakibart
igAN
&
Novartis Q4 Results | January 31, 2024
20View entire presentation